FDA Approval for Gazyva®/Gazyvaro® (obinutuzumab) in Lupus Nephritis
Roche has received U.S. FDA approval for Gazyva®/Gazyvaro® (obinutuzumab) for the treatment of adults with active lupus nephritis, used in combination with standard therapy. This approval marks a significant step forward in the management of this complex autoimmune disease, offering patients a new therapeutic option with a shorter 90-minute infusion time.
Why This Milestone Matters
- Lupus nephritis impacts more than 1.7 million individuals worldwide, predominantly women.
- Around one-third of patients progress to end-stage kidney disease, underscoring the urgent need for effective therapies.
- Gazyva/Gazyvaro is the only anti-CD20 antibody proven to improve complete renal response in a Phase III clinical study.
Key Findings from the REGENCY Phase III Trial
- 46.4% of patients achieved complete renal response compared with 33.1% receiving standard therapy alone.
- Demonstrated improvements in proteinuria, complement levels, and anti-dsDNA antibodies, along with reduced corticosteroid use.
- The safety profile remained consistent with existing oncology indications.
What This Means for Clinicians and Patients
This approval introduces a potential new standard of care, providing healthcare professionals with an effective and convenient treatment option to help preserve kidney function and slow disease progression.
Greenstaff Life Sciences congratulates Roche and Genentech on this milestone in advancing care for patients living with lupus nephritis.